Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes
Authors
Keywords
-
Journal
CARDIOVASCULAR RESEARCH
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2019-12-10
DOI
10.1093/cvr/cvz323
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
- (2019) Kristina S. Boye et al. DIABETES OBESITY & METABOLISM
- The Interconnection Between Immuno-Metabolism, Diabetes, and CKD
- (2019) Fabrizia Bonacina et al. Current Diabetes Reports
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatic triglyceride content does not affect circulating CETP: lessons from a liraglutide intervention trial and a population-based cohort
- (2019) Huub J. van Eyk et al. Scientific Reports
- GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials
- (2019) Søren L Kristensen et al. Lancet Diabetes & Endocrinology
- Diabetes, cardiovascular disease and the microcirculation
- (2018) W. David Strain et al. Cardiovascular Diabetology
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
- (2018) Daniel J. Drucker Cell Metabolism
- Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and kidney clearance: Post-hoc analyses of four clinical trials
- (2018) Lennart Tonneijck et al. DIABETES OBESITY & METABOLISM
- Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus PatientsNovelty and Significance
- (2018) Lennart Tonneijck et al. HYPERTENSION
- Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis
- (2018) Raffaele Marfella et al. Diabetology & Metabolic Syndrome
- Effect of glycaemic control on cardiovascular disease in individuals with type 2 diabetes with pre-existing cardiovascular disease: A systematic review and meta-analysis
- (2018) Yael Barer et al. DIABETES OBESITY & METABOLISM
- Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2018) Melanie J. Davies et al. DIABETOLOGIA
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial
- (2018) Marcel H A Muskiet et al. Lancet Diabetes & Endocrinology
- GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes
- (2017) Marcel H. A. Muskiet et al. Nature Reviews Nephrology
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Renal Outcomes in Type 2 Diabetes
- (2017) Johannes F.E. Mann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
- (2017) Paul M Ridker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Difference in protective effects of GIP and GLP-1 on endothelial cells according to cyclic adenosine monophosphate response
- (2017) Dong-Mee Lim et al. Experimental and Therapeutic Medicine
- Glucagon-like peptide-1 receptor agonists and atrial fibrillation: a systematic review and meta-analysis of randomised controlled trials
- (2017) M. Monami et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice
- (2017) Laurie L. Baggio et al. Molecular Metabolism
- GLP-1–Based Therapies Have No Microvascular Effects in Type 2 Diabetes MellitusHighlights
- (2016) Mark M. Smits et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males
- (2016) Mark M. Smits et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Effects of Liraglutide on Heart Rate and Heart Rate Variability: A Randomized, Double-Blind, Placebo-Controlled Crossover Study
- (2016) Preman Kumarathurai et al. DIABETES CARE
- A meta-analysis comparing clinical effects of short- or long-acting GLP-1 receptor agonists versus insulin treatment from head-to-head studies in type 2 diabetic patients
- (2016) Mirna S. Abd El Aziz et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial
- (2016) Mark M Smits et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial
- (2016) Anders Jorsal et al. EUROPEAN JOURNAL OF HEART FAILURE
- GLP-1 based therapies: clinical implications for gastroenterologists
- (2016) Mark M Smits et al. GUT
- No benefit of additional treatment with exenatide in patients with an acute myocardial infarction
- (2016) Sebastiaan T. Roos et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions
- (2016) Michael G. Silverman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction
- (2016) Kenneth B. Margulies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Role of Vasopressin in the Regulation of Renal Sodium Excretion: Interaction with Glucagon-Like Peptide-1
- (2016) A. V. Kutina et al. JOURNAL OF NEUROENDOCRINOLOGY
- Arterial Effects of Canakinumab in Patients With Atherosclerosis and Type 2 Diabetes or Glucose Intolerance
- (2016) Robin P. Choudhury et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
- (2016) Dena Ettehad et al. LANCET
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
- (2016) Robert A. Scott et al. Science Translational Medicine
- Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure
- (2016) David Nathanson et al. Diabetology & Metabolic Syndrome
- A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction
- (2016) Kasper Kyhl et al. EuroIntervention
- Effects of the Novel Long-Acting GLP-1 Agonist, Albiglutide, on Cardiac Function, Cardiac Metabolism, and Exercise Capacity in Patients With Chronic Heart Failure and Reduced Ejection Fraction
- (2016) John J. Lepore et al. JACC-Heart Failure
- GLP-1 Receptor Agonist Exenatide Increases Capillary Perfusion Independent of Nitric Oxide in Healthy Overweight Men
- (2015) M. M. Smits et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Dulaglutide: A Review in Type 2 Diabetes
- (2015) Celeste B. Burness et al. BIODRUGS
- Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus
- (2015) Keiichi Torimoto et al. Cardiovascular Diabetology
- Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis
- (2015) Feng Sun et al. CLINICAL THERAPEUTICS
- Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
- (2015) Juraj Koska et al. DIABETES
- Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis
- (2015) Feng Sun et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Albiglutide: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
- (2015) Hannah A. Blair et al. DRUGS
- Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel
- (2015) Christoph Kapitza et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance
- (2015) Kim A. Sjøberg et al. JOURNAL OF PHYSIOLOGY-LONDON
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
- (2015) Miles Fisher et al. Lancet Diabetes & Endocrinology
- The effect of liraglutide on endothelial function in patients with type 2 diabetes
- (2014) Debashis Nandy et al. Diabetes & Vascular Disease Research
- Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes
- (2014) Antonio Ceriello et al. DIABETES CARE
- Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus
- (2014) Keith C. Ferdinand et al. HYPERTENSION
- Pressure natriuresis and the renal control of arterial blood pressure
- (2014) Jessica R. Ivy et al. JOURNAL OF PHYSIOLOGY-LONDON
- Ability of GLP-1 to decrease food intake is dependent on nutritional status
- (2014) Charlotte C. Ronveaux et al. PHYSIOLOGY & BEHAVIOR
- GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle
- (2013) Kim A. Sjøberg et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Cardioprotective Effects of Exenatide in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
- (2013) Jong Shin Woo et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Glucagon-Like Peptide-1 (GLP-1): Effect on Kidney Hemodynamics and Renin-Angiotensin-Aldosterone System in Healthy Men
- (2013) Jeppe Skov et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure
- (2013) Minsuk Kim et al. NATURE MEDICINE
- Acute peripheral administration of synthetic human GLP-1 (7–36 amide) decreases circulating IL-6 in obese patients with type 2 diabetes mellitus: A potential role for GLP-1 in modulation of the diabetic pro-inflammatory state?
- (2013) Christina Daousi et al. REGULATORY PEPTIDES
- Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males
- (2013) Jeppe Skov et al. Endocrine Connections
- Exenatide, a Glucagon-like Peptide-1 Receptor Agonist, Acutely Inhibits Intestinal Lipoprotein Production in Healthy Humans
- (2012) Changting Xiao et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Investigation of the haemodynamic effects of exenatide in healthy male subjects
- (2012) Buddhike Mendis et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: Results from an observational research
- (2012) Concetta Irace et al. Diabetes & Vascular Disease Research
- Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study
- (2012) M. Nauck et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
- (2012) Juris J. Meier Nature Reviews Endocrinology
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- Hyperlipidemia as a Risk Factor for Cardiovascular Disease
- (2012) Robert H. Nelson PRIMARY CARE
- Long-Acting Glucagon-Like Peptide 1 Receptor Agonists: A review of their efficacy and tolerability
- (2011) A. J. Garber DIABETES CARE
- DURATION-2: efficacy and safety of switching from maximum daily sitagliptin or pioglitazone to once-weekly exenatide
- (2011) C. Wysham et al. DIABETIC MEDICINE
- Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction
- (2011) Jacob Lønborg et al. EUROPEAN HEART JOURNAL
- A thorough QT study to evaluate the effects of singledose exenatide 10 μg on cardiac repolarization in healthy subjects
- (2011) H. Linnebjerg et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- DURATION-5: Exenatide Once Weekly Resulted in Greater Improvements in Glycemic Control Compared with Exenatide Twice Daily in Patients with Type 2 Diabetes
- (2011) Thomas Blevins et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus
- (2010) Eric A. Schwartz et al. ATHEROSCLEROSIS
- Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study
- (2010) Anne Gill et al. Cardiovascular Diabetology
- Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4
- (2010) M. Arakawa et al. DIABETES
- The Glucagonostatic and Insulinotropic Effects of Glucagon-Like Peptide 1 Contribute Equally to Its Glucose-Lowering Action
- (2010) K. J. Hare et al. DIABETES
- Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database
- (2010) J. H. Best et al. DIABETES CARE
- Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial
- (2010) Michaela Diamant et al. LANCET
- Cerebral Salt Wasting: Pathophysiology, Diagnosis, and Treatment
- (2010) Alan H. Yee et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
- (2009) R. A. DeFronzo DIABETES
- Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
- (2009) B. Zinman et al. DIABETES CARE
- Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)
- (2009) M. Marre et al. DIABETIC MEDICINE
- Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
- (2009) D. Russell-Jones et al. DIABETOLOGIA
- Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
- (2009) John B Buse et al. LANCET
- Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans
- (2008) Adil E. Bharucha et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
- (2008) Daniel J Drucker et al. LANCET
- Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial
- (2008) Alan Garber et al. LANCET
- Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting
- (2008) W Todd Cade PHYSICAL THERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now